Monumental Financial Group Inc. Has $1.63 Million Position in Eli Lilly and Company (NYSE:LLY)

Monumental Financial Group Inc. reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 3.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,803 shares of the company’s stock after selling 108 shares during the period. Eli Lilly and Company makes up about 1.0% of Monumental Financial Group Inc.’s investment portfolio, making the stock its 16th biggest position. Monumental Financial Group Inc.’s holdings in Eli Lilly and Company were worth $1,634,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Lipe & Dalton acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $35,000. Optiver Holding B.V. bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $36,000. Finally, Family CFO Inc bought a new stake in Eli Lilly and Company in the third quarter valued at approximately $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

LLY stock traded up $8.64 during trading hours on Friday, reaching $733.51. The stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The stock has a market capitalization of $696.95 billion, a PE ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a 50-day simple moving average of $761.79 and a 200 day simple moving average of $667.10. Eli Lilly and Company has a fifty-two week low of $380.77 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.09 earnings per share. Analysts predict that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on LLY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday, April 15th. Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.